Cellular Health Screening Market

Cellular Health Screening Market Size (2023 to 2028)

The size of the global cellular health screening market is estimated to grow by USD 5.48 Billion by 2028 from USD 3.48 Billion in 2023, registering a CAGR of 9.5% during the forecast period.

Individuals can use cellular health screening to gain a quick and simple understanding of their health on a cellular level. Professionals may use the technology to identify areas that require immediate attention and create an individualized plan to achieve effective outcomes. For example, fat mass, cellular toxicity, intracellular and extracellular fluid levels, cellular health and function, and muscle mass quality may all be determined with cellular health screening. In addition, people can use technology to keep track of their general health, particularly if they want to know whether they have any chronic conditions that might be deadly. Furthermore, governmental impositions and limitations on transportation, export, and import of products, raw materials, and other products disrupt the supply chain during the pandemic. As a result, demand has decreased, and many companies have shifted their product portfolios from cellular health testing to COVID-19 molecular testing.

Cellular health screening provides a cellular-level review of health, which helps doctors and practitioners understand how the body works and functions on a cellular level. Cellular health screening is essential in precision medicine since it allows easy monitoring and control of therapy methods. It also provides information on muscle tone and mass, and cellular activity, which has expanded its use in routine health screenings. Personal or suggested cellular health screenings are available. Within a tissue culture incubator, a live cell analysis system allows for real-time, quantitative live-cell tests. The system enables tests to be carried out and findings to be sent. There are other single-test cellular health screening kits on the market. The use of home-based diagnostics is growing rapidly across the world. Public awareness programs focused on recognizing the signs of chronic diseases and preventing them are crucial in limiting disease spread. Using these devices also eliminates the need to wait for test results to be decrypted and assist in optimizing timely treatment decisions, improving the efficacy of care provided and significantly lowering diagnosis costs, particularly in resource-constrained settings with inadequate laboratory infrastructure.

MARKET DRIVERS:

The cellular health screening market is driven by increased cellular health screening applications in personalized medicine across the world and the rising adoption of telomere performance programs to lead a healthy life. Furthermore, the growing geriatric population worldwide and increasing research activities are more likely to accelerate the market's growth rate. In addition, the growing adoption of the direct-to-consumer approach for cellular health screening and the rising burden of chronic diseases are expected to augment the market growth.

Moreover, the increasing government's focus on healthcare and investments to improve healthcare infrastructure is anticipated to create a positive environment for the market to explore further. Furthermore, rising awareness among the people about cellular health screening and growing focus on preventive healthcare services worldwide with the government's support and the rising incidences of genetic disorders is further expected to fuel the global cellular health screening market. Furthermore, an increasing number of cancer patients due to changes in lifestyles, food habits and the growing geriatric population is fuelling the growth of the cellular health screening market.

MARKET RESTRAINTS:

Rapid changes in economic strategies, the high cost of test kits, and difficulties in transporting samples from one place to another are the biggest challenges the global cellular health screening market faces. Risks involved with transporting samples are projected to restrain cellular health screenings' market growth. On the other hand, rapidly changing economic strategies and the high cost of kits required for screening impede market growth.

Impact of COVID-19 on the global cellular health screening market:

The unexpected emergence of COVID-19 has positively impacted the pharmaceutical and global sciences industries. However, the global cellular health screening market had a slight decline in its growth rate in 2019 due to the situations caused by COVID-19. The cellular health screening market had substantial growth before the introduction of the pandemic. However, the sudden outbreak has changed the market structure and growth. When the World Health Organization announced COVID-19 as a hospital emergency, the governments implemented a nationwide lockdown to stop the virus transmission. An increase in the COVID-19 positive cases had prolonged the lockdown period, and hence concerned cellular health screening procedures had also been postponed. During the COVID-19 period, the primary focus of the hospitals and government was to combat COVID-19. Capital and investment in cellular health treatments had been diverted to the COVID-19 fight. The research on telomeres has seen a spike in the recent past and the field of telomeres has changed dramatically post the covid-19 pandemic period. Clinicians are interested in incorporating telomere testing into their practices due to the rising understanding of telomere play's role in personalized medicines. Hence, the market runs towards recovery and is expected to fall in its growth path by the end of 2021.

REPORT COVERAGE:

This report segmented and sub-segmented the Global Cellular Health Screening Market into the following categories.

Cellular Health Screening Market – By Test Panels Type:

• Single Test Panels               
  • Telomere Tests
  • Inflammation Tests
  • Oxidative Stress Tests
  • Heavy Metal Tests
• Multi-Test Panels  

Based on Test Panels Type, because they are used to acquire more accurate information and aid in completing cellular health screening tests to assess telomere length, single test panels are projected to dominate the market. Therefore, the telomere testing sub-segment has the largest share of this market. In addition, these panels give reliable data and help assess screening tests' effective performance to assess telomere length, therefore avoiding illnesses. As a result, the market for preventive healthcare screening goods and services is expected to grow.

Cellular Health Screening Market – By Sample Type:

• Blood Samples
• Other Samples

Based on the sample type, because clinicians most often use blood samples to evaluate organ functioning, diagnose illnesses and disorders, analyze risk factors, determine pharmaceutical efficacy, and test blood clotting, the Blood sample segment retained most of the market share. In addition, the launch of novel blood-based cellular health screening tests has aided the segment's expansion.

Cellular Health Screening Market – By Sample Collection Site:

• In-Office Sample Collection
• At-Home Sample Collection
• Other Sample Collection

Based on Sample Collection Site, Due to the rising acceptance of self-sampling in major countries, which is user-friendly and does not require specialist lab infrastructure or expert training, At Home Sample collection segment is expected to grow at the quickest CAGR during the forecast period. In addition, due to lockdowns and movement restrictions in key economies, the worldwide COVID-19 epidemic has bolstered the home sample collection market.

Cellular Health Screening Market – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• The Middle East and Africa

Geographically, North America has the leading market for cellular health screening globally, which Europe and the Asia Pacific regions follow. North America is dominating the highest shares of the market by quickly adopting the latest technologies and introducing innovative devices in favor of the end-users. Increasing focus to ensure patients' safety is outshining the market's growth rate. North America currently holds the largest revenue share in the global cellular health screening market, and this trend is anticipated to continue throughout the forecast period. This dominance can be ascribed to a rise in awareness of HALE, which has been declining throughout the region. The industry is expected to increase as chronic diseases become more common and the global geriatric population grows. Telomere testing has also become more popular as people's lifestyles have changed. Furthermore, increased research efforts and adopting the direct-to-consumer approach for kit availability are other drivers contributing to the market expansion. The United States has the largest proportion of the regional market. The existence of significant market players, simple availability of telomere and oxidative stress tests, high adoption of test-from-home, and rising awareness about uncommon diseases are all factors leading to its dominance.

The Asia Pacific and Europe are following North America are leading the highest shares of the global cellular health screening market with the increasing scale of pharmaceutical companies.   Due to the existence of the target population and improved healthcare infrastructure in developing nations, Asia Pacific is expected to be the fastest-growing regional market. Other factors boosting the regional market are emerging nations' increased acceptance and awareness of telomere performance programs.

The Middle East and Africa are anticipated to have inclined growth rates in the coming years with the rise in funds from private and public organizations on research institutes. Also, the rising demand for self-medication is gearing up the need for the cellular health screening market.

KEY MARKET PARTICIPANTS:

Some of the major players in the global cellular health screening market profiled in this report are Genova Diagnostics (U.S.), Quest Diagnostics (U.S.), Telomere Diagnostics (U.S.), Life Length (Spain), Repeat Diagnostics (Canada), SpectraCell Laboratories (U.S.), Zimetry LLC (U.S.), Cell Science Systems (U.S.), Titanovo, Inc. (U.S.), Segterra, Inc. (U.S.), LabCorp Holdings (U.S.), BioReference Laboratories (U.S.), Immundiagnostik AG (Germany) and Cleveland HeartLab, Inc. (U.S.).

RECENT MARKET HAPPENINGS:

• In 2016, teloyears was launched by Telomere and its new telomere test.
• Teloyears evaluate an individual's telomeres and biomarkers that change with age. Teloyears are easy to use. Telomeres in white blood cells are assessed and summarized in a report to be sent back to the test taker. Teloyears Diagnostics developed the test, teloyears. Unlike other genetic tests, teloyears are based on biomarkers that change over time.
• In 2015, spectra cell expanded its specialized testing menu to include several new diagnostic panels for cardiometabolic biomarkers, prediabetic screening, thyroid, male and female hormone panels, and cardiovascular-related genetic tests.
• In 2015, a saliva-based telomere testing kit was launched by Titanovo.  This kit permits the users to measure their telomeres' length; the kit users need only to use a cotton swab provided by the company. Titanovo provides clients with data correlating their telomere length to regional, genealogical, genetic, and environmental factors. In addition, researchers provided anonymous health information through the test, which is expected to lead to medical breakthroughs in the future.
• In 2016, a partnership was made between Life length and Eastern Biotech & Life sciences to launch telomere tests in GCC countries.